Goodyear M D, Mackay I R, Russell I S
Cancer Chemother Pharmacol. 1981;7(1):37-40. doi: 10.1007/BF00258211.
A study was made on the recovery of the bone marrow after adjuvant chemotherapy given to 30 post-mastectomy patients with stage II breast cancer treated with either melphalan or melphalan and methotrexate at 6-weekly intervals for 1 year. Counts of peripheral blood cells were made serially during treatment and then for a further 2 years after stopping chemotherapy. Mean counts for all cell types fell during chemotherapy and recovery was long-delayed. Thus 24 months after chemotherapy, mean counts for total leucocytes and platelets were significantly lower than mean pretreatment counts and counts for a normal female population, and the count for neutrophils was significantly lower than the count before treatment; after 24 months mean counts for lymphocytes were not significantly depressed. Melphalan was assumed to be the agent responsible. Slow haematological recovery after cessation of adjuvant chemotherapy with one particular regimen points to the need for including long-term post-chemotherapy observation of the bone marrow in the assessment of adjuvant chemotherapy programmes.
对30例II期乳腺癌乳房切除术后患者进行了一项研究，这些患者接受了美法仑或美法仑与甲氨蝶呤联合治疗，每6周一次，持续1年。在治疗期间连续进行外周血细胞计数，化疗停止后再持续2年。化疗期间所有细胞类型的平均计数均下降，恢复延迟。因此，化疗24个月后，总白细胞和血小板的平均计数显著低于治疗前平均计数和正常女性人群的计数，中性粒细胞计数显著低于治疗前计数；24个月后淋巴细胞的平均计数没有显著降低。推测美法仑是造成这种情况的药物。采用一种特定方案辅助化疗停止后血液学恢复缓慢，这表明在评估辅助化疗方案时需要纳入化疗后对骨髓的长期观察。
